SY

Syncom Formulations (India) LtdNSE SYNCOMF

Последний отчетный период 31 мар., 2024

Обновлено 19 сент., 2024

Последняя цена

Капитализация млрд. $

0.07

Micro

Биржа

XNSE - National Stock Exchange Of India

Анализ акций SYNCOMF.NS

SY

Нет оценки

Количественный анализ Eyestock не покрывает акции Syncom Formulations (India) Ltd.

Капитализация млрд. $

0.07

Дивидендная доходность

Оборот

940 млрд

Сайт компании

https://syncomformulations.com/

Syncom Formulation India Ltd. is a pharmaceutical company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Indore, Madhya Pradesh and currently employs 799 full-time employees. The firm is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. The company is also engaged in the renting of properties. The company manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The firm's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.

Смотреть Секцию: Рейтинг